CTOT | Approved Studies

Protocol	Study Status	Title	Principal Investigator
CTOT-01	Closed	Noninvasive Monitoring to Predict Outcome in de novo Kidney Transplant Recipients	Peter Heeger, MD
CTOT-02/CCTPT-02	Closed	B-Cell Depletion by Anti-CD20 in Renal Allograft Recipients who Develop de novo Anti HLA Alloantibodies	Mohamed Sayegh, MD and Anil Chandraker, MD
CTOT-03	Closed	Correlation of Donor Proinflammatory mRNA Profiles with Early Outcomes of Thoracic and Abdominal Transplantation	Abraham Shaked, MD
CTOT-04	Closed	Noninvasive Diagnosis of Renal Allograft Rejection by Urinary Cell mRNA Profiling	Abraham Shaked, MD
CTOT-05	Closed	Observational Study of Alloimmunity in Cardiac Transplant Recipients	Peter Heeger, MD; Mohamed Sayegh, MD; and Anil Chandraker, MD
CTOT-06	Closed	A Mechanistic Substudy of the Bristol-Myers Squibb Sponsored Trial "Belatacept Conversion Trial in Renal Transplantation	Mohamed Sayegh, MD
CTOT-07	Closed	Development of Genomic Signatures for the Prediction, Diagnosis and Prognostication of Liver Allograft Rejection and recurrent Hepatitis C Disease	Abraham Shaked, MD, PhD
CTOT-08	Closed	Discovery and Validation of Proteogenomic Biomarker Panels in a Prospective Serial Blood and Urine Monitoring Study of Kidney Transplant Recipients - Transplant Proteogenomics	Michael Abecassis, MD, MBA
CTOT-09	Closed	Immune Monitoring and CNI Withdrawal in Low Risk Recipients of Kidney Transplantation	Peter S. Heeger, MD
CTOT-10	Closed	Optimization of Belatacept Usage As A Means of Avoiding CNI and steroids in Renal Transplantation	Christian P. Larsen, MD and Kenneth Newell, MD, PhD
CTOT-11	Closed	Prevention of Cardiac Allograft Vasculopathy Using Rituximab (Rituxan®) Therapy in Cardiac Transplantation	Mohamed Sayegh, MD
ITN524ST-CTOT-12	Closed	Associating Renal Transplantation with the ITN Signature of Tolerance (ARTIST)	Kenneth Newell, MD, PhD; Laurence Turka, MD; Anil Chandraker, MD
CTOT-13	Closed	A Prospective, Randomized, Multicenter, Two-Parallel Arm Study Evaluating the Overall Efficacy and Safety of Desensitization Therapy on Selected Patients Awaiting Heart Transplantation	Peter S. Heeger, MD
CTOT-14	Closed	Discovery and Validation of Proteogenomic Biomarker Panels in a Prospective Serial Blood and Urine Monitoring Study of Liver Transplant Recipients - Transplant Proteogenomics	Michael Abecassis, MD, MBA
CTOT-15	Closed	Optimaztion of NULOJIX® (Belatacept) Usage as a Means of Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation	Kenneth A. Newell, MD, PhD
CTOT-16	Closed	Optimaztion of NULOJIX® (Belatacept) Usage as a Means of Avoiding CNI and Steroids in Renal Transplantation	Kenneth A. Newell, MD, PhD
CTOT-17	Closed	A Retrospective Multicenter Study to Determine 5-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-01 Study	Peter S Heeger, MD
CTOT-18	Closed	A Retrospective Multicenter Study to Determine 4-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-05 Study	Peter S Heeger, MD
CTOT-19	Closed	Randomized Controlled Trial of Remicade Induction Therapy for Deceased Donor Kidney Transplant Recipients	Peter S Heeger, MD
CTOT-20	Closed	A Prospective Multicenter Observational Cohort Study to Define the Risks Factors and Mechanisms of Chronic Lung Allograft Dysfunction (CLAD) Phenotypes	Scott M. Palmer, MD, MHS
CTOT-21	Active, Not Recruiting	Treg Adoptive Therapy in Subclinical Inflammation in Kidney Transplantation	Flavio Vincenti, MD
CTOT-22	Closed	Prospective Multicenter Cytomegalovirus (CMV) Specific Immune Monitoring to Predict Patient Risk after Lung Transplantation	Scott M. Palmer, MD, MHS
CTOT-23	Closed	A Retrospective, Multicenter, Study to Determine Up to 5 Year Clinical Outcomes in Subjects Previously Randomized in CTOT-11 Study	Peter S Heeger, MD, Anil Chandraker, MD
CTOT-24	Active, Not Recruiting	Regulatory T Cell Modulation in Kidney Transplantation With Biologic Blockade of Dual Effector Pathways, CD28 and IL-6	Flavio Vincenti, MD




	Home > Public	Click here to login. \|